

Luca Valenti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1873025/luca-valenti-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

389
papers

33,813
citations

74
h-index

178
g-index

480
ext. papers

41,045
ext. citations

6.7
avg, IF

7.13
L-index

#	Paper	IF	Citations
389	PSD3 downregulation confers protection against fatty liver disease.. <i>Nature Metabolism</i> , 2022 , 4, 60-75	14.6	1
388	Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients.. <i>European Journal of Clinical Investigation</i> , 2022 , e13753	4.6	3
387	Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of .. <i>Science Translational Medicine</i> , 2022 , 14, eabh3831	17.5	2
386	Global multi-stakeholder endorsement of the MAFLD definition.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	18
385	The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 869006	5.7	1
384	Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. <i>International Journal of Obesity</i> , 2021 ,	5.5	2
383	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 ,	7.9	6
382	Red blood cell morphology in patients with COVID-19-related anaemia. <i>Blood Transfusion</i> , 2021 , 19, 34-36	3.6	13
381	SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. <i>Blood Transfusion</i> , 2021 , 19, 181-189	3.6	41
380	Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. <i>Transfusion</i> , 2021 , 61, 3381-3389	2.9	4
379	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
378	Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. <i>Nature Communications</i> , 2021 , 12, 1822	17.4	3
377	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. <i>EBioMedicine</i> , 2021 , 65, 103249	8.8	1
376	A Role in the Genetic Predisposition to NAFLD-HCC?. <i>Cancers</i> , 2021 , 13,	6.6	5
375	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 2021 ,		5
374	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. <i>Cells</i> , 2021 , 10,	7.9	6
373	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. <i>Cancers</i> , 2021 , 13,	6.6	6

372	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , 2021 , 160, 1634-1646.e7	13.3	23
371	Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2021 , 74, 1494-1496	13.4	2
370	Natural history of NASH. <i>Liver International</i> , 2021 , 41 Suppl 1, 78-82	7.9	4
369	Prognostic parameters of in-hospital mortality in COVID-19 patients-An Italian experience. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13629	4.6	12
368	A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	12
367	Current management of NAFLD/NASH. <i>Liver International</i> , 2021 , 41 Suppl 1, 89-94	7.9	2
366	Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. <i>JHEP Reports</i> , 2021 , 3, 100262	10.3	4
365	Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	9
364	Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. <i>JHEP Reports</i> , 2021 , 3, 100284	10.3	7
363	COVID-19 and the liver: A 2021 update. <i>Liver International</i> , 2021 , 41, 1988-1998	7.9	8
362	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. <i>Gut</i> , 2021 , 70, 180-193	19.2	39
361	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021 , 74, 775-782	13.4	50
360	PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021 , 41, 321-332	7.9	10
359	Genetic insight into COVID-19-related liver injury. <i>Liver International</i> , 2021 , 41, 227-229	7.9	9
358	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. <i>Journal of Autoimmunity</i> , 2021 , 116, 102560	15.5	57
357	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , 2021 , 74, 20-30	13.4	24
356	Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?. <i>Lancet Haematology</i> , 2021 , 8, e8-e10	14.6	
355	Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3

354	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2021 ,	19.2	27
353	Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. <i>Journal of Autoimmunity</i> , 2021 , 117, 102595	15.5	19
352	Clinical Determinants of Disease Progression in Patients With Beta-Sarcoglycan Gene Mutations. <i>Frontiers in Neurology</i> , 2021 , 12, 657949	4.1	1
351	Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. <i>Diabetes Research and Clinical Practice</i> , 2021 , 177, 108882	7.4	0
350	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. <i>Seminars in Liver Disease</i> , 2021 , 41, 421-434	4.3	9
349	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 2712-2719	7.9	3
348	Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. <i>Nature Communications</i> , 2021 , 12, 4878	17.4	5
347	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. <i>Internal and Emergency Medicine</i> , 2021 , 1	3.7	3
346	Is there an Ideal Diet for patients with NAFLD?. <i>European Journal of Clinical Investigation</i> , 2021 , e13659	4.6	2
345	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. <i>Journal of Hepatology</i> , 2021 , 75, 506-513	13.4	8
344	Liver Field during Immunotherapy of Hepatocellular Carcinoma: Some Like It Hot. <i>Gastroenterology</i> , 2021 , 161, 1065-1067	13.3	1
343	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. <i>Hepatology Communications</i> , 2021 , 5, 1824-1832	6	3
342	Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008-2019. <i>Liver International</i> , 2021 ,	7.9	4
341	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021 , 75, 770-785	13.4	19
340	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 786-794	13.4	21
339	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	15
338	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. <i>Journal of Autoimmunity</i> , 2021 , 124, 102728	15.5	1
337	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. <i>Molecular Metabolism</i> , 2021 , 53, 101275	8.8	2

336	Genetic risk scores and personalization of care in fatty liver disease. <i>Current Opinion in Pharmacology</i> , 2021 , 61, 6-11	5.1	2
335	PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 1-11	6.4	0
334	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	2
333	Genetic variants in the MTHFR are not associated with fatty liver disease. <i>Liver International</i> , 2020 , 40, 1934-1940	7.9	1
332	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1522-1534	59.2	913
331	Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. <i>Blood</i> , 2020 , 136, 766-768	2.2	31
330	Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. <i>Hepatology</i> , 2020 , 72, 330-346	11.2	36
329	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020 , 73, 26-39	13.4	137
328	Prevalence and 9-year incidence of hepatitis E virus infection among North Italian blood donors: Estimated transfusion risk. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 858-861	3.4	7
327	Update on NAFLD genetics: From new variants to the clinic. <i>Journal of Hepatology</i> , 2020 , 72, 1196-1209	13.4	85
326	PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. <i>Liver International</i> , 2020 , 40, 1130-1141	7.9	16
325	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemic. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1576-1578	9.5	6
324	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. <i>EBioMedicine</i> , 2020 , 52, 102658	8.8	36
323	Approach to the patient with chronic hepatitis B and decompensated cirrhosis. <i>Liver International</i> , 2020 , 40 Suppl 1, 22-26	7.9	5
322	Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020 , 73, 361-370	13.4	11
321	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
320	Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. <i>Liver International</i> , 2020 , 40, 769-777	7.9	11
319	Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1639-1646	3.9	8

318	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020 , 73, 593-602	13.4	28
317	Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020 , 31, 969-986.e7	24.6	44
316	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
315	Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020 , 26, 998-1009	3.3	6
314	The Natural History of NAFLD: Environmental vs. Genetic Risk Factors 2020 , 129-145		1
313	Lack of genetic evidence that fatty liver disease predisposes to COVID-19. <i>Journal of Hepatology</i> , 2020 , 73, 709-711	13.4	14
312	Impact of natural neuromedin-B receptor variants on iron metabolism. <i>American Journal of Hematology</i> , 2020 , 95, 167-177	7.1	2
311	Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. <i>Cell Metabolism</i> , 2020 , 31, 35-45	24.6	64
310	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. <i>Digestive and Liver Disease</i> , 2020 , 52, 359-367	3.3	2
309	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020 , 31, 406-421.e7	24.6	69
308	Association of ABO blood group and secretor phenotype with severe COVID-19. <i>Transfusion</i> , 2020 , 60, 3067-3070	2.9	16
307	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
306	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020 , 1865, 158765	5	4
305	Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. <i>Hepatology</i> , 2020 , 72, 1912-1923	11.2	18
304	Management of Acute Hepatitis B Virus Infection. <i>Current Hepatology Reports</i> , 2020 , 19, 276-284		1
303	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3. <i>American Journal of Pathology</i> , 2020 , 190, 2226-2236	5.8	12
302	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1289-1292	0.7	5
301	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020 , 73, S13-S14	13.4	3

300	Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. <i>Endocrinology, Diabetes and Metabolism</i> , 2020 , 3, e00179	2.7	5
299	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 517-519	6.9	8
298	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , 2020 , 72, 88-102	11.2	46
297	KLHL30 gene variation is associated with liver damage in children with NAFLD. <i>Journal of Hepatology</i> , 2020 , 72, 411-419	13.4	27
296	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
295	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. <i>Gut</i> , 2020 , 69, 1855-1866	19.2	34
294	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. <i>Atherosclerosis</i> , 2019 , 282, 110-120	3.1	45
293	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Liver International</i> , 2019 , 39, 1742-1754	7.9	37
292	PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis. <i>Journal of Hepatology</i> , 2019 , 70, e109-e110	13.4	4
291	FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2019 , 51, e26	3.3	3
290	Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2019 , 96, 56-65	12.7	24
289	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019 , 70, 1913-1927	11.2	111
288	gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. <i>Journal of Lipid Research</i> , 2019 , 60, 1144-1153	6.3	27
287	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 3682	4.9	42
286	Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: A systematic review. <i>Liver International</i> , 2019 , 39, 1521-1534	7.9	14
285	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2310-2319.e6	6.9	42
284	Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. <i>Molecular Metabolism</i> , 2019 , 22, 49-61	8.8	83
283	Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial. <i>Frontiers in Neurology</i> , 2019 , 10, 755	4.1	12

282	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. <i>Scientific Reports</i> , 2019 , 9, 11585	4.9	44
281	Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges. <i>Journal of Hepatology</i> , 2019 , 71, 849-850	13.4	2
280	Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	16
279	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. <i>Digestive and Liver Disease</i> , 2019 , 51, 1586-1592	3.3	22
278	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019 , 70, 1521-1530	11.2	113
277	NAFLD in children: new genes, new diagnostic modalities and new drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 517-530	24.2	105
276	mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. <i>Nutrients</i> , 2019 , 11,	6.7	19
275	Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. <i>World Journal of Gastroenterology</i> , 2019 , 25, 6094-6106	5.6	7
274	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2019 , 45, 480-487	5.4	22
273	Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology. <i>Journal of Lipid Research</i> , 2019 , 60, 7-8	6.3	4
272	Financial Compensation For Hepatologists in Different Practice Settings. <i>Hepatology</i> , 2019 , 69, 2664-2671	11.2	3
271	Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. <i>Liver International</i> , 2019 , 39, 250-256	7.9	22
270	Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C). <i>Antiviral Therapy</i> , 2019 , 24, 35-44	1.6	8
269	Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update. <i>Current Pharmaceutical Design</i> , 2018 , 24, 4566-4573	3.3	20
268	Nonalcoholic Fatty Liver Disease in Children. <i>Seminars in Liver Disease</i> , 2018 , 38, 1-13	7.3	59
267	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018 , 69, 18-24	13.4	68
266	The next wave of hepatitis C virus: The epidemic of intravenous drug use. <i>Liver International</i> , 2018 , 38 Suppl 1, 34-39	7.9	20
265	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. <i>Journal of Internal Medicine</i> , 2018 , 283, 356-370	10.8	140

264	Hepatic iron is the major determinant of serum ferritin in NAFLD patients. <i>Liver International</i> , 2018 , 38, 164-173	7.9	38
263	Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease. <i>Metabolic Brain Disease</i> , 2018 , 33, 347-352	3.9	4
262	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018 , 69, 1365-1370	13.4	29
261	Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development. <i>Journal of Hepatology</i> , 2018 , 68, S31	13.4	2
260	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. <i>World Journal of Hepatology</i> , 2018 , 10, 231-245	3.4	9
259	Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. <i>Atherosclerosis</i> , 2018 , 268, 27-31	3.1	9
258	The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom. <i>Clinics in Liver Disease</i> , 2018 , 22, 109-119	4.6	29
257	Genetics and epigenetics of NAFLD and NASH: Clinical impact. <i>Journal of Hepatology</i> , 2018 , 68, 268-279	13.4	362
256	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	85
255	FGF23 and Fetuin-A Interaction in the Liver and in the Circulation. <i>International Journal of Biological Sciences</i> , 2018 , 14, 586-598	11.2	9
254	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018 , 2, 666-675	6	30
253	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017 , 49, 471-483	3.3	179
252	Impact of hepatitis C virus therapy on metabolism and public health. <i>Liver International</i> , 2017 , 37 Suppl 1, 13-18	7.9	19
251	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017 , 37, 1389-1396	7.9	26
250	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2017 , 131, 1301-1315	6.5	38
249	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2660-2669	5.6	30
248	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1604-1611.e1	6.9	83
247	Developing a relationship with a liver transplant program. <i>Clinical Liver Disease</i> , 2017 , 9, 73-76	2.2	

246	HFE mutations and iron in hemodialysis patients. <i>Hemodialysis International</i> , 2017 , 21 Suppl 1, S47-S57	1.7	4
245	Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. <i>Gastroenterology</i> , 2017 , 153, 1568-1580.e10	13.3	13
244	The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. <i>Scientific Reports</i> , 2017 , 7, 9273	4.9	14
243	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
242	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. <i>Journal of Hepatology</i> , 2017 , 66, S593	13.4	7
241	Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. <i>Current Hepatology Reports</i> , 2017 , 16, 169-177	1	3
240	myVCF: a desktop application for high-throughput mutations data management. <i>Bioinformatics</i> , 2017 , 33, 3676-3678	7.2	6
239	Interferon lambda 4 rs368234815 TT>G variant is associated with liver damage in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017 , 66, 1885-1893	11.2	59
238	Iron overload induces hypogonadism in male mice via extrahypothalamic mechanisms. <i>Molecular and Cellular Endocrinology</i> , 2017 , 454, 135-145	4.4	8
237	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017 , 7, 4492	4.9	131
236	GNPAT p.D519G variant and iron metabolism during oral iron tolerance test. <i>Hepatology</i> , 2017 , 65, 384-385	3.5	3
235	S18-1APPLYING GENETIC INFORMATION ON HEPATOCELLULAR CARCINOMA SURVEILLANCE STRATEGIES [ARE WE THERE YET?]. <i>Alcohol and Alcoholism</i> , 2017 , 52, i4-i30	3.5	
234	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. <i>Annals of Hepatology</i> , 2017 , 16, 451-456	3.1	11
233	A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	39
232	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. <i>Annals of Hepatology</i> , 2017 , 16, 451-456	3.1	9
231	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. <i>Liver International</i> , 2016 , 36, 1563-1579	7.9	96
230	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. <i>Human Molecular Genetics</i> , 2016 , 25, 5212-5222	5.6	71
229	Reply to "Statin treatment for non-alcoholic steatohepatitis". <i>Journal of Hepatology</i> , 2016 , 64, 242-3	13.4	

228	Reply. <i>Hepatology</i> , 2016 , 63, 1052-3	11.2	
227	Hepcidin resistance in dysmetabolic iron overload. <i>Liver International</i> , 2016 , 36, 1540-8	7.9	22
226	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 229-42	4.2	32
225	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 682-90	13.4	79
224	Universal screening for chronic hepatitis C virus. <i>Liver International</i> , 2016 , 36 Suppl 1, 62-6	7.9	21
223	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. <i>Gastroenterology</i> , 2016 , 150, 1219-1230.e6	13.3	347
222	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. <i>Atherosclerosis</i> , 2016 , 246, 208-13	3.1	61
221	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , 2016 , 48, 120-37	3.3	23
220	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 333-42	3.3	42
219	Genetics of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 1026-37	12.7	67
218	Nutritional therapy for nonalcoholic fatty liver disease. <i>Journal of Nutritional Biochemistry</i> , 2016 , 29, 1-11	6.3	72
217	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	88
216	Telomeres, NAFLD and Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 383	6.3	37
215	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0162473	3.7	34
214	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0163069	3.7	45
213	Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFE-related hemochromatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1342-8	4	9
212	PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 134-40	4.5	18
211	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. <i>Hepatology</i> , 2016 , 63, 787-98	11.2	70

210	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. <i>Hepatology</i> , 2016 , 63, 418-27	11.2	29
209	Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 816-823	4.9	24
208	Liver fat accumulation is associated with circulating PCSK9. <i>Annals of Medicine</i> , 2016 , 48, 384-91	1.5	78
207	Particulate matter phagocytosis induces tissue factor in differentiating macrophages. <i>Journal of Applied Toxicology</i> , 2016 , 36, 151-60	4.1	6
206	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015 , 61, 506-14	11.2	311
205	The UCP2 -866G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. <i>Liver International</i> , 2015 , 35, 1574-80	7.9	35
204	Oxidative Stress and Hepatic Iron Overload. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2015 , 345-356		2
203	PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity. <i>Journal of Nutrition</i> , 2015 , 145, 1687-91	4.1	59
202	Cure of HCV related liver disease. <i>Liver International</i> , 2015 , 35 Suppl 1, 71-7	7.9	20
201	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. <i>Hepatology</i> , 2015 , 62, 111-7	11.2	46
200	Increased circulating adiponectin in males with chronic HCV hepatitis. <i>European Journal of Internal Medicine</i> , 2015 , 26, 635-9	3.9	5
199	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015 , 8, 1037-46	4.1	42
198	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. <i>Clinical Epigenetics</i> , 2015 , 7, 61	7.7	66
197	Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E821-5	5.6	55
196	Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2015 , 163, 809-17	8	68
195	High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. <i>PLoS ONE</i> , 2015 , 10, e0116855	3.7	30
194	Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. <i>BioMed Research International</i> , 2015 , 2015, 460190	3	89
193	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , 2015 , 63, 705-12	3.4	227

192	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015 , 373, 2608-17	59.2	613
191	Reply: To PMID 25251399. <i>Hepatology</i> , 2015 , 62, 660	11.2	6
190	Iron Stores, Hcpidin, and Aortic Stiffness in Individuals with Hypertension. <i>PLoS ONE</i> , 2015 , 10, e0134635	3.7	21
189	HCV F1/F2 patients: treat now or continue to wait. <i>Liver International</i> , 2014 , 34 Suppl 1, 79-84	7.9	7
188	Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. <i>Molecular and Cellular Endocrinology</i> , 2014 , 382, 860-70	4.4	13
187	Hcpidin levels in chronic hemodialysis patients: a critical evaluation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014 , 52, 613-9	5.9	21
186	The role of interferon in the new era of hepatitis C treatments. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 649-56	4.2	5
185	Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. <i>Genes and Nutrition</i> , 2014 , 9, 392	4.3	38
184	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014 , 61, 148-54	13.4	113
183	Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). <i>Digestive and Liver Disease</i> , 2014 , 46, 18-24	3.3	9
182	My treatment approach to chronic hepatitis C virus. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 934-42	6.4	3
181	A population-based study on the prevalence of NASH using scores validated against liver histology. <i>Journal of Hepatology</i> , 2014 , 60, 839-46	13.4	89
180	Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients. <i>Antiviral Therapy</i> , 2014 , 19, 747-53	1.6	6
179	A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014 , 58, 632-6	2.8	58
178	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. <i>Annals of Hepatology</i> , 2014 , 13, 568-571	3.1	4
177	Long term changes in liver histology following treatment of chronic hepatitis C virus. <i>Annals of Hepatology</i> , 2014 , 13, 340-349	3.1	32
176	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. <i>Hepatology International</i> , 2014 , 8, 517-26	8.8	5
175	CDKN1A: a double-edged sword in fatty liver?. <i>Cell Cycle</i> , 2014 , 13, 1371-2	4.7	7

174	Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 627-33	4.6	21
173	Role of iron in hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2014 , 3, 108-110	2.2	14
172	Reply: To PMID 24114809. <i>Hepatology</i> , 2014 , 60, 1111-2	11.2	
171	Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. <i>Hepatology</i> , 2014 , 59, 2170-7	11.2	156
170	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. <i>Human Molecular Genetics</i> , 2014 , 23, 4077-85	5.6	230
169	Deciphering the role of β fatty acids in nonalcoholic steatohepatitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014 , 59, 423-4	2.8	3
168	The PNPLA3 I148M variant and chronic liver disease: When a genetic mutation meets nutrients. <i>Food Research International</i> , 2014 , 63, 239-243	7	5
167	Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e96349	3.7	23
166	Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C. <i>PLoS ONE</i> , 2014 , 9, e106022	3.7	9
165	A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3002-10	5.6	66
164	Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12945-55	5.6	98
163	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. <i>Annals of Hepatology</i> , 2014 , 13, 568-71	3.1	1
162	Dietary iron overload induces visceral adipose tissue insulin resistance. <i>American Journal of Pathology</i> , 2013 , 182, 2254-63	5.8	101
161	The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. <i>BMC Nephrology</i> , 2013 , 14, 48	2.7	17
160	Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. <i>Diabetes</i> , 2013 , 62, 4052-62	0.9	65
159	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. <i>Journal of Hepatology</i> , 2013 , 58, 399-401	13.4	11
158	A 360-degree overview of paediatric NAFLD: recent insights. <i>Journal of Hepatology</i> , 2013 , 58, 1218-29	13.4	120
157	Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. <i>International Journal of Obesity</i> , 2013 , 37, 986-92	5.5	33

156	PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. <i>Digestive and Liver Disease</i> , 2013 , 45, 619-24	3.3	42
155	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2013 , 58, S46	13.4	6
154	Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. <i>Liver International</i> , 2013 , 33 Suppl 1, 105-10	7.9	18
153	IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2013 , 45, 348-9	3.3	2
152	Cobalamin as a regulator of serum and cerebrospinal fluid levels of normal prions. <i>Journal of Clinical Neuroscience</i> , 2013 , 20, 134-8	2.2	5
151	Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?. <i>PPAR Research</i> , 2013 , 2013, 452061	4.3	17
150	Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. <i>BioMed Research International</i> , 2013 , 2013, 580796	3	3
149	The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. <i>Journal of Medicinal Food</i> , 2013 , 16, 957-60	2.8	49
148	Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. <i>Hepatology</i> , 2013 , 58, 1245-52	11.2	56
147	Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5219-38	3.3	148
146	PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2013 , 8, e74089	3.7	47
145	Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2013 , 2013, 145421	6.7	81
144	PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2013 , 8, e75982	3.7	36
143	PNPLA3 I148M polymorphism and progressive liver disease. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6969-78	5.6	153
142	A novel alpha1-antitrypsin null variant (PiQ0Milano). <i>World Journal of Hepatology</i> , 2013 , 5, 458-61	3.4	7
141	Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1434-42	6.1	32
140	T-ARMS-PCR for the evaluation of rs12979860 IL28B genotype: an optimized protocol. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 228-228	3.4	2
139	Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. <i>Hepatology</i> , 2012 , 55, 336-42	11.2	67

138	IL28B, HCV core mutations, and hepatocellular carcinoma: does host genetic make-up shape viral evolution in response to immunity?. <i>Hepatology International</i> , 2012 , 6, 356-9	8.8	3
137	Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. <i>International Journal of Molecular Medicine</i> , 2012 , 30, 49-56	4.4	46
136	315 I148M PNPLA3 POLYMORPHISM IS ASSOCIATED WITH CLINICAL FEATURES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2012 , 56, S129	13.4	4
135	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. <i>Journal of Hepatology</i> , 2012 , 57, 1319-25	13.4	27
134	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. <i>Journal of Hepatology</i> , 2012 , 56, 448-54	13.4	126
133	Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. <i>Journal of Hepatology</i> , 2012 , 56, 1209-1210	13.4	17
132	The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. <i>BMC Gastroenterology</i> , 2012 , 12, 111	3	50
131	PNPLA3 Ile148Met variant and hepatocellular carcinoma: a matter of fat. <i>Digestive and Liver Disease</i> , 2012 , 44, 974-5	3.3	3
130	The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2012 , 7, e48804	3.7	37
129	I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology. <i>Hepatology</i> , 2012 , 56, 791	11.2	20
128	Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?. <i>Liver International</i> , 2012 , 32 Suppl 1, 54-60	7.9	22
127	LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012 , 54, 588-93	2.8	46
126	Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2012 , 7, e41183	3.7	38
125	Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. <i>World Journal of Gastroenterology</i> , 2012 , 18, 2813-20	5.6	42
124	Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 3782-6	5.6	31
123	Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. <i>World Journal of Nephrology</i> , 2012 , 1, 166-76	3.6	23
122	I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology. <i>Hepatology</i> , 2012 , 56, 1883-9	11.2	9
121	Interferon-free regimens: the near future, the likely and the not so likely. <i>Clinics in Liver Disease</i> , 2011 , 15, 665-75	4.6	5

120	T-12 Echocardiographic epicardial fat thickness in non alcoholic fatty liver disease: A possible marker of metabolic syndrome and early vascular damage. <i>Digestive and Liver Disease</i> , 2011 , 43, S80-S81 ^{3,3}	2
119	Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. <i>Digestive and Liver Disease</i> , 2011 , 43, 89-95	3.3 58
118	1280 DIETARY IRON OVERLOAD INDUCES VISCERAL ADIPOSE TISSUE INSULIN RESISTANCE ASSOCIATED WITH HYPER-RESISTINEMIA, AND SYNERGIZES WITH OBESITY AND FATTY LIVER IN INDUCING SYSTEMIC INSULIN RESISTANCE. <i>Journal of Hepatology</i> , 2011 , 54, S505	13.4 5
117	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. <i>Journal of Hepatology</i> , 2011 , 54, 1244-9	13.4 82
116	Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011 , 55, 69-75	13.4 137
115	Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2011 , 55, 647-653	13.4 27
114	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. <i>Journal of Hepatology</i> , 2011 , 55, 1409-14	13.4 65
113	Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2011 , 55, 1470-1; author reply 1471-2	13.4 14
112	Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. <i>Journal of Hepatology</i> , 2011 , 55, 920-32	13.4 205
111	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011 , 21, 568-75	4.5 62
110	Modulation of Iron Metabolism and Hcpidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications 2011 ,	1
109	A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 628-30	3.4 22
108	PNPLA3 I148M polymorphism and liver damage in obese children. <i>Journal of Pediatrics</i> , 2011 , 159, 876	3.6 3
107	HCV Response-Guided Therapy: Should Treatment Length Be Shortened or Extended?. <i>Current Hepatitis Reports</i> , 2011 , 10, 4-10	5
106	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. <i>Hepatology</i> , 2011 , 53, 791-9	11.2 199
105	Patatin-like phospholipase domain-containing protein 3 genotype and hepatocellular carcinoma in chronic hepatitis C. <i>Hepatology</i> , 2011 , 53, 1777-1777	11.2 5
104	Patatin-like phospholipase domain containing-3 Ile148Met and fibrosis progression after liver transplantation. <i>Hepatology</i> , 2011 , 54, 1484	11.2 8
103	Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 1293-301	2.9 7

102	Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 683-90 ⁹⁻⁴	67
101	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling—a propensity score-adjusted observational study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011 , 104, 141-9	2.7 49
100	Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic βcell mass expansion. <i>Diabetes</i> , 2011 , 60, 3217-22	0.9 44
99	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2010 , 59, 267-73	19.2 117
98	Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus. <i>Oncology</i> , 2010 , 78 Suppl 1, 11-6	3.6 6
97	A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. <i>Hormone and Metabolic Research</i> , 2010 , 42, 854-9	3.1 33
96	Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. <i>Translational Research</i> , 2010 , 156, 226-8	11 2
95	HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2010 , 138, 905-12	13.3 203
94	Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. <i>Journal of Hepatology</i> , 2010 , 52, 832-8	13.4 45
93	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2010 , 53, 927-33	13.4 51
92	Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. <i>Gastroenterology</i> , 2010 , 139, 120-9.e18	13.3 582
91	14 A DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION. <i>Journal of Hepatology</i> , 2010 , 52, S7	13.4 6
90	Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. <i>American Journal of Pathology</i> , 2010 , 176, 1006-17	5.8 54
89	Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2072-8	0.7 50
88	Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. <i>Hepatology</i> , 2010 , 51, 501-10	11.2 31
87	Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. <i>Hepatology</i> , 2010 , 51, 388-97	11.2 127
86	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 1209-17	11.2 445
85	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 1274-80	11.2 200

84	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. <i>BMC Gastroenterology</i> , 2010 , 10, 102	3	46
83	HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1331-7	6.9	24
82	Reply:. <i>Hepatology</i> , 2009 , 49, 697-697	11.2	
81	Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations?. <i>Internal and Emergency Medicine</i> , 2009 , 4, 91-2	3.7	3
80	Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. <i>Osteoporosis International</i> , 2009 , 20, 549-55	5.3	121
79	The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?. <i>Seminars in Immunopathology</i> , 2009 , 31, 359-69	12	72
78	What future for ribavirin?. <i>Liver International</i> , 2009 , 29 Suppl 1, 68-73	7.9	22
77	Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. <i>New England Journal of Medicine</i> , 2009 , 361, 580-93	59.2	1041
76	Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. <i>Digestive and Liver Disease</i> , 2009 , 41, e17-20	3.3	3
75	Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. <i>Gastroenterology</i> , 2009 , 137, 1986-94	13.3	29
74	Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response. <i>Antiviral Therapy</i> , 2009 , 14, 143-154	1.6	14
73	Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2008 , 48, 513-4; author reply 514-5	13.4	3
72	Carotid artery intima-media thickness in nonalcoholic fatty liver disease. <i>American Journal of Medicine</i> , 2008 , 121, 72-8	2.4	164
71	Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. <i>American Journal of Pathology</i> , 2008 , 172, 738-47	5.8	124
70	Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors. <i>Clinics in Liver Disease</i> , 2008 , 12, 487-505, vii	4.6	16
69	Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations: response to Equitani et al. <i>Diabetes Care</i> , 2008 , 31, e18; author reply e19	14.6	8
68	Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. <i>Diabetes</i> , 2008 , 57, 1355-62	0.9	128
67	HFE genotype influences erythropoiesis support requirement in hemodialysis patients: a prospective study. <i>American Journal of Nephrology</i> , 2008 , 28, 311-6	4.6	11

66	Role and support for hepatologists at liver transplant programs in the United States. <i>Liver Transplantation</i> , 2008 , 14, 1092-9	4.5	19
65	HFE mutations in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2008 , 47, 1794-5; author reply 1795-6	11.2	11
64	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. <i>Hepatology</i> , 2008 , 48, 792-8	11.2	481
63	Risk of severe liver disease in nonalcoholic fatty liver disease: Role of insulin resistance. <i>Hepatology</i> , 2008 , 48, 2088-2088	11.2	2
62	The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. <i>Journal of Rheumatology</i> , 2008 , 35, 153-8	4.1	36
61	Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. <i>Gastroenterology</i> , 2007 , 132, 103-12	13.3	173
60	A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2007 , 46, 297-306	11.2	252
59	Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. <i>Hepatology</i> , 2007 , 46, 371-9	11.2	175
58	The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. <i>Hepatology</i> , 2007 , 46, 1091-100	11.2	84
57	Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. <i>Haematologica</i> , 2007 , 92, 1037-42	6.6	60
56	A balancing view: We cannot do it alone. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1841-3	0.7	8
55	Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1251-8	0.7	234
54	Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. <i>American Journal of Gastroenterology</i> , 2007 , 102, 761-6	0.7	47
53	HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. <i>American Journal of Nephrology</i> , 2007 , 27, 101-7	4.6	19
52	Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. <i>New England Journal of Medicine</i> , 2007 , 357, 124-34	59.2	469
51	Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. <i>Current Gastroenterology Reports</i> , 2006 , 8, 46-52	5	17
50	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. <i>Current Hepatitis Reports</i> , 2006 , 5, 114-120		
49	Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. <i>Hepatology</i> , 2006 , 43, 682-9	11.2	381

48	Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. <i>Hepatology</i> , 2006 , 44, 857-64	11.2	74
47	Circulating ghrelin levels in patients with inflammatory bowel disease. <i>Gut</i> , 2006 , 55, 432-3	19.2	37
46	Chronic hepatitis C in patients with persistently normal alanine transaminase levels. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 645-52	6.9	66
45	Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2006 , 44, 679-85	13.4	39
44	TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. <i>Journal of Hepatology</i> , 2005 , 43, 944-50	13.4	32
43	Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. <i>Blood Cells, Molecules, and Diseases</i> , 2005 , 35, 27-32	2.1	22
42	Iron and insulin resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22 Suppl 2, 61-3	6.1	60
41	Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. <i>Journal of Biological Chemistry</i> , 2005 , 280, 20589-95	5.4	409
40	TNFalpha promoter polymorphisms. <i>Methods in Molecular Medicine</i> , 2004 , 98, 47-58		8
39	Chronic hepatitis C. <i>Seminars in Liver Disease</i> , 2004 , 24 Suppl 2, 1-2	7.3	3
38	Treatment choices for people infected with HCV. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 53, 708-12	3.1	11
37	Hepatitis C with normal liver enzymes: to treat or not to treat. A balancing view: a decision to be shared with patients. <i>American Journal of Gastroenterology</i> , 2004 , 99, 975-6	0.7	2
36	The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. <i>Journal of Medical Genetics</i> , 2004 , 41, 946-50	5.8	65
35	Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. <i>Alcohol and Alcoholism</i> , 2004 , 39, 276-80	3.5	20
34	Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. <i>Liver Transplantation</i> , 2004 , 10, 1248-55	4.5	119
33	A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 1107-15	6.9	331
32	Searching for coeliac disease in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2004 , 36, 333-6	3.3	57
31	Retreatment of patients who do not respond to initial therapy for chronic hepatitis C. <i>Cleveland Clinic Journal of Medicine</i> , 2004 , 71 Suppl 3, S13-6	2.8	5

30	Side effects of medical therapy for chronic hepatitis C. <i>Annals of Hepatology</i> , 2004 , 3, 5-10	3.1	11
29	Management of patients with chronic hepatitis C virus infection and previous nonresponse. <i>Reviews in Gastroenterological Disorders</i> , 2004 , 4 Suppl 1, S22-30		6
28	Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. <i>Hepatology</i> , 2003 , 37, 1286-92	11.2	766
27	Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. <i>Digestive and Liver Disease</i> , 2003 , 35, 172-8	3.3	66
26	TNFalpha promoter polymorphisms in Italian patients with porphyria cutanea tarda. <i>Digestive and Liver Disease</i> , 2003 , 35, 596-7	3.3	1
25	Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. <i>Gastroenterology</i> , 2003 , 124, 866; author reply 866-7	13.3	34
24	What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers?. <i>Metabolism: Clinical and Experimental</i> , 2003 , 52, 1593-6	12.7	10
23	Retreatment of patients with chronic hepatitis C. <i>Hepatology</i> , 2002 , 36, S128-S134	11.2	30
22	Retreatment of patients with chronic hepatitis C. <i>Hepatology</i> , 2002 , 36, S128-34	11.2	21
21	Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2002 , 122, 274-80	13.3	253
20	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , 2002 , 347, 975-82	59.2	5551
19	TNF alpha polymorphisms, HFE gene mutations and acquired factors in Italian patients with porphyria cutanea tarda. <i>Journal of Hepatology</i> , 2002 , 36, 157-158	13.4	53
18	Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. <i>Blood</i> , 2001 , 97, 3707-12	2.2	80
17	A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. <i>Hepatology</i> , 2001 , 34, 395-403	11.2	495
16	Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2448-55	0.7	179
15	Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. <i>Gastroenterology</i> , 2001 , 120, 1183-92	13.3	1546
14	Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells. <i>British Journal of Haematology</i> , 2000 , 110, 978-84	4.5	47
13	Hereditary hemochromatosis in a patient with congenital dyserythropoietic anemia. <i>Blood</i> , 2000 , 96, 3653-3655	2.2	10

12	The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. <i>Hepatology</i> , 1999 , 30, 602-5	11.2	19
11	Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. <i>New England Journal of Medicine</i> , 1998 , 339, 1485-92	59.2	2960
10	Treatment of fulminant hepatic failure with intravenous prostaglandin E1. <i>Liver Transplantation</i> , 1998 , 4, 424-31		18
9	A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. <i>Hepatology</i> , 1995 , 22, 759-766	11.2	200
8	The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the national digestive diseases advisory board. <i>Hepatology</i> , 1995 , 22, 1591-1597	11.2	135
7	The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the national digestive diseases advisory board 1995 , 22, 1591		6
6	Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. <i>Hepatology</i> , 1994 , 19, 933-940	11.2	59
5	Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis 1994 , 19, 933		1
4	rs641738C>T near MBOAT7 is positively associated with liver fat, ALT, and histological severity of NAFLD: a meta-analysis		3
3	SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak		40
2	The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis		23
1	A Sustainable Development Goal framework to guide multisectoral action on NAFLD through a societal approach		1